Biogen price target lowered to $200 from $215 at Barclays

Barclays lowered the firm’s price target on Biogen to $200 from $215 and keeps an Equal Weight rating on the shares post the Q1 report. Skyclarys and Leqembi showed momentum, albeit against low expectations, while Spinraza’s outlook was ratcheted lower, the analyst tells investors in a research note. The firm says a GLP-1 overhang is looming for Biogen.